Αρχική World News Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma World News Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Από Ogkologos - 16 Μαρτίου, 2026 402 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... 17 Ιανουαρίου, 2023 Neoadjuvant Chemotherapy with mFOLFIRINOX Followed by Chemoradiotherapy Improves Survival in Patients... 14 Αυγούστου, 2024 Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does... 6 Οκτωβρίου, 2021 Keeping A Jasmine Plant In Your Room Reduces Anxiety, Panic Attacks... 12 Απριλίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab... How My Metastatic Cancer Diagnosis Led Me to a Full-Time Career... Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In? ESMO Sarcoma and Rare Cancers Congress 2024